Speedy advances in innovation and technology and increasing maturity in the application of artificial intelligence, big data analytics, genomics and other technologies have expedited the growth of the healthcare industry worldwide.
On 1 July, the National Healthcare Security Administration and the National Health Commission jointly announced multiple measures to support the high-quality development of innovative drugs. Priority is to be given to supporting innovative drug research and development (R&D), the inclusion of new drugs in insurance drug catalogues and their use in clinical application, diversifying payment channels for innovative drugs, and more.
The increasing emphasis on healthcare by most countries is strengthening the global demand for medical supplies, while worldwide trade networks are vital links driving the development of the industry. In light of this, HKTDC Research interviewed Savewo Ltd at the 16th Hong Kong International Medical and Healthcare Fair.
The healthcare sector is undergoing a dynamic transformation, fuelled by breakthroughs in biotechnology and innovations in life sciences. During the HKTDC Asia Summit on Global Health, held alongside the 16th HK International Medical and Healthcare Fair, an on-site survey was conducted from 26-28 May 2025, to obtain professional insights on the industry’s outlook.
As the application of artificial intelligence (AI) plays an increasingly important role in people’s daily lives, the senior-care products market is no exception. According to Hanshin Technology Limited, a Hong Kong smart-technology company and an exhibitor at the 16th Hong Kong International Medical and Healthcare Fair, the elderly face various daily challenges while products empowered by AI technology can help improve their quality of life and reshape their lifestyles.
Protective medical industry had undergone a process of weeding out the weak and retaining the strong. As the market consolidates and evolves rapidly, Action Medical has expanded its Hong Kong production line of quality face masks and developed its local and overseas sales business in earnest. Using Hong Kong as a base, it is also actively setting foot into related protective medical product fields and expanding its business into emerging markets.
On 20 June 2025, the European Commission (“Commission”) announced that it has decided to exclude Chinese companies from EU government purchases of medical devices exceeding €5 million. This measure follows the conclusions of the first investigation under the EU’s International Procurement Instrument.
Medical services extend beyond traditional treatments to include a comprehensive array of healthcare offerings, such as assisted reproduction. In an interview with HKTDC Research, Incinta Medical Group elaborated that assisted reproduction services encompass several specialized medical areas. With its diversified biopharmaceutical industry and international business environment, Hong Kong is strategically positioned to support the company's efforts in pursuing technological collaborations for further expansion.